# Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

Study · id `cardio:ct-nct02884206` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02884206](<https://clinicaltrials.gov/study/NCT02884206>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02884206

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 592 participants.

## Technical summary

Registry record NCT02884206. Randomized; double masking; primary purpose treatment. Start 2016-11-23 (actual); primary completion 2022-05-16 (actual). Results posted on 2024-08-06.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 592 participants (enrolled count; ClinicalTrials.gov record NCT02884206, source copy `cardio:ctgov-nct02884206-2024-08-06`, retrieved 2026-10-26)
- Started: 2016-11-23 (actual) (ClinicalTrials.gov record NCT02884206, source copy `cardio:ctgov-nct02884206-2024-08-06`, retrieved 2026-10-26)
- Primary completion: 2022-05-16 (actual) (ClinicalTrials.gov record NCT02884206, source copy `cardio:ctgov-nct02884206-2024-08-06`, retrieved 2026-10-26)
- Completion: 2022-05-16 (actual) (ClinicalTrials.gov record NCT02884206, source copy `cardio:ctgov-nct02884206-2024-08-06`, retrieved 2026-10-26)
- Results first posted: 2024-08-06 (ClinicalTrials.gov record NCT02884206, source copy `cardio:ctgov-nct02884206-2024-08-06`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Belgium; Bulgaria; Canada; Croatia; France; Germany; Italy; Lithuania; Netherlands; Poland; Russia; South Korea; Spain; Switzerland; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT02884206, source copy `cardio:ctgov-nct02884206-2024-08-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02884206-2024-08-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
- Acronym: PERSPECTIVE
- Condition: Chronic Heart Failure (CHF)
- Intervention (Drug): LCZ696
- Intervention (Drug): Valsartan
- Intervention (Drug): Placebo of LCZ696
- Intervention (Drug): Placebo of Valsartan
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Sacubitril/valsartan (combination) (`cardio:sacubitril-valsartan`)
- Registry intervention name matches this record: Valsartan (`cardio:valsartan`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 0215804bb3aeb33eb070e5adc54732d4d4747c6b7598283cbd86a11f34bd0873
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
